Get started
Author

Tomoiki Aiba

Observed names: T. Aiba, T. aiba
ORCID: 0000-0001-8991-237X
Observed ORCID: 0000-0001-8991-237X
OpenAlex ID: A5041388408
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · JAMA Oncology · 359
PDF
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · The Oncologist · 299
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
2019 · Mari Aso, Yukihiro Toi, et al. · The Oncologist · 58
PDF
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)
2025 · Taiki Hakozaki, Kentaro Tanaka, et al. · Journal of Thoracic Oncology · 26
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
2019 · Jun Sugisaka, Yukihiro Toi, et al. · JMA Journal · 25
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
2021 · Kana Ono, Hirotaka Ono, et al. · Cancer Medicine · 21
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers
2021 · Tomoiki Aiba, Chieko Hattori, et al. · PLoS ONE · 11
PDF
Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial ( JMTO LC14 ‐01)
2023 · Susumu Takeuchi, Kaoru Kubota, et al. · Cancer Medicine · 10
PDF
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
2019 · Yukihiro Toi, Yuichiro Kimura, et al. · Sarcoidosis vasculitis and diffuse lung diseases · 10
PDF
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome
2024 · Soichiro Minami, Yosuke Kawashima, et al. · Cancer Reports · 5
PDF
Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase ( ALK)‐positive lung cancer and multiple brain metastases
2024 · Yosuke Murakami, Yosuke Kawashima, et al. · Cancer Reports · 4
PDF
Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
2019 · J. Sugisaka, S. Sugawara, et al. · Annals of Oncology · 4
PDF
The mammalian homolog of the Drosophila discs large tumor suppressor protein up-regulates expression of the ELR+ CXC chemokine Scyb5
2005 · Tomoiki Aiba, Kazuyoshi Kohu, et al. · Biochemical and Biophysical Research Communications · 3
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer
2025 · Soichiro Minami, Tsuyoshi Doman, et al. · Translational Lung Cancer Research · 2
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer
2026 · Tomoiki Aiba, Shuichiro Hara, et al. · Lung Cancer · 1
662P Comparison of atezolizumab/etoposide/platinum and durvalumab/etoposide/platinum for extensive-stage small cell lung cancer in Japan: A multicenter retrospective observational study
2024 · H. Sakashita, T. Aiba, et al. · Annals of Oncology · 1
PDF
Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
2023 · Jun Sugisaka, Yukihiro Toi, et al. · Thoracic Cancer · 1
PDF
P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
2019 · Y. Toi, S. Sugawara, et al. · Journal of Thoracic Oncology · 1
A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab
2019 · Atsushi Nakamura, Tomoiki Aiba, et al. · Haigan · 1
PDF
P2.07-004 Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients
2017 · Y. Toi, S. Sugawara, et al. · Journal of Thoracic Oncology · 1
Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report
2026 · Takahiro Ogasawara, Yukihiro Toi, et al. · Journal of Medical Case Reports
Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC
2026 · Masahiro Torasawa, Yoshihiro Masui, et al. · Journal of Thoracic Oncology
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer: TRAP-OLIGO study (WJOG11118L).
2026 · Hideyuki Harada, Taichi Miyawaki, et al. · Journal of Clinical Oncology
Necitumumab plus pembrolizumab and chemotherapy for untreated advanced squamous NSCLC: Phase I/II NEJ048A/NEXUS.
2026 · Tomoiki Aiba, Akihiko Miyanaga, et al. · Journal of Clinical Oncology
Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound EGFR -mutated non-small cell lung cancer (WJOG17323L: AGEHA study).
2026 · Taichi Miyawaki, Takehito Shukuya, et al. · Journal of Clinical Oncology
PDF
Works count: 37
Citation count: 842
H-index: 9
I10-index: 9
Year
Topic
Type